Dr Katharine Carter

Senior Lecturer

Strathclyde Institute of Pharmacy and Biomedical Sciences

Personal statement

I have two main areas of research interests: the study of leishmaniasis and drug delivery. My research on leishmaniasis has been involved in understanding the underlying immunological mechansims involved in the control of the disease, the mechananism responible for drug resistance, and development of novel vaccine fomulations to control the infection. I work on L. donovani, L. major and L. mexicana and we have recently started using luciferase-expressing parasites to track the infection. My drug delivery studies have focused on using non-ionic surfactant vesicles (NIV) to improve drug delivery by the intravenous or pulmonary routes. We are currently involved in commercialising NIV for the pulmonary delivery ('Inhalosomes') through the spin-out comany 'Inhalosome-C Ltd', which is involved in developing a cisplatin product for the treatment of lung cancer.

B10 Fo luc cells imaged using the IVIS® system

Cells were treated with an anticancer drug (columns 3-10) - with the highest concentration in colum 3 and the lowest in column 10. Column 2 shows the results for the control cells and column 11 shows the results for the negative control. This type of assay is used for screening anticancer compounds.

Publications

Selective anti-Leishmanial Strathclyde minor groove binders using an N-oxide tail group modification: Perieteanu Marina C, McGee Leah MC, Shaw Craig D, MacMillan Donna S, Khalaf Abedawn I, Gillingwater Kirsten, Beveridge Rebecca, Carter Katharine C, Suckling Colin J, Scott Fraser J; International Journal of Molecular Sciences Vol 23 (2022); https://doi.org/10.3390/ijms231911912
Intranasally administered S-MGB-364 displays antitubercular activity and modulates the host immune response to mycobacterium tuberculosis infection: Kieswetter Nathan S, Ozturk Mumin, Hlaka Lerato, Chia Julius Ebua, Nichol Ryan J O, Cross Jasmine M, McGee Leah, Tyson-Hirst Izaak, Beveridge Rebecca, Brombacher Frank, Carter Katharine C, Suckling Colin J, Scott Fraser J, Guler Reto; Journal of Antimicrobial Chemotherapy Vol 77, pp. 1061-1071 (2022); https://doi.org/10.1093/jac/dkac001
Correction : Truncated S-MGBs: towards a parasite-specific and low aggregation chemotype: Brooke Daniel P, McGee Leah M C, Giordani Federica, Cross Jasmine M, Khalaf Abedawn I, Irving Craig, Gillingwater Kirsten, Shaw Craig D, Carter Katharine C, Barrett Michael P, Suckling Colin J, Scott Fraser J; RSC Medicinal Chemistry Vol 12, pp. 2071-2071 (2021); https://doi.org/10.1039/d1md90044g
Truncated S-MGBs : towards a parasite-specific and low aggregation chemotype: Brooke Daniel P, McGee Leah M C, Giordani Federica, Cross Jasmine M, Khalaf Abedawn I, Irving Craig, Gillingwater Kirsten, Shaw Craig D, Carter Katharine C, Barrett Michael P, Suckling Colin J, Scott Fraser J; RSC Medicinal Chemistry Vol 12, pp. 1391-1401 (2021); https://doi.org/10.1039/D1MD00110H
Antileishmanial efficacy and tolerability of combined treatment with non-ionic surfactant vesicle formulations of sodium stibogluconate and paromomycin in dogs: Miret Jorge A, Moreno Javier, Nieto avier, Carter Katharine C, Mullen Alexander B, Ambros Luis, Rodríguez Casilda, San Andrés Manuel Ignacio, González Fernado; Experimental Parasitology Vol 220 (2021); https://doi.org/10.1016/j.exppara.2020.108033
Drug combinations as effective anti-leishmanials against drug resistant Leishmania mexicana: Ahmed Humera, Curtis Charlotte R, Tur-Gracia Sara, Olatunji Toluwanimi O, Carter Katharine C, Williams Roderick A M; RSC Medicinal Chemistry Vol 11, pp. 905-912 (2020); https://doi.org/10.1039/D0MD00101E

More publications

Professional activities

4th Worldleish Congress on Leishmaniasis 2009 in Lucknow, India: Keynote/plenary speaker; 2009

More professional activities

Projects

Genes in Action Curiosity Box: A Hands-on Resource Kit for the Introduction of Primary School Children to the Topic of DNA, Inheritance and Cell and Gene Therapy: Carter, Katharine (Principal Investigator); 01-Jan-2021 - 28-Jan-2022
Screening antileishmania drugs: Carter, Katharine (Principal Investigator); 04-Jan-2018 - 31-Jan-2018
Development of a vaccine against leishmaniasis (Vacation Scholarship): Carter, Katharine (Principal Investigator); 06-Jan-2016 - 17-Jan-2016
Development of starting materials for cell-based treatments (project plan for SMART grant): Carswell, Hilary (Principal Investigator) Carter, Katharine (Co-investigator) Currie, Susan (Co-investigator) Pickard, Ben (Co-investigator) Williams, Roderick (Co-investigator) McKittrick, Craig (Researcher); 01-Jan-2015 - 31-Jan-2016
Development of a diagnostic test for lesihmaniasis: Carter, Katharine (Principal Investigator); 12-Jan-2013 - 31-Jan-2014
KTA Application: Development of a commercially viable non- ionic surfactant vesicle amphotericin B formulation.: Carter, Katharine (Principal Investigator) Ferro, Valerie (Principal Investigator) Mullen, Alexander (Principal Investigator); Improve AMB-NIV formulation; 08-Jan-2012 - 30-Jan-2012

More projects

Address

Strathclyde Institute of Pharmacy and Biomedical Sciences
Hamnett Wing

Location Map

View University of Strathclyde in a larger map